CLINICAL_TRIALS
trial_result
· 2023-01-09
Clinical Trial Update: CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients [Phase 2]
Summary
Phase 2 trial update for CAMPath and belimumab in sensitized kidney transplant recipients was terminated; results published in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Wisconsin, Madison | Conditions: Kidney Transplantation | Phase 2 | Status: TERMINATED | Results posted: 2023-01-09